Novo Nordisk’s Oral Wegovy Wins EU Approval, but a Strict Dosing Regimen and Mounting Rivalry Chec
The European Commission’s green light for Novo Nordisk’s oral Wegovy tablet on 15 July 2026 marks the first…
Novo Nordisk Faces Mounting Challenges as Competition Intensifies
Novo Nordisk cuts 2026 sales outlook amid generic competition in India, U.S. price pressures, and Eli Lilly’s new…
Novo Nordisk Shares Face Mounting Regulatory and Market Challenges
Novo Nordisk receives FDA warning over safety reporting delays but secures a new sales channel for Ozempic and…
Novo Nordisk Faces Mounting Pressure as Rival Gains Ground
Novo Nordisk faces intense competition from Eli Lilly in the $100B obesity drug market, with clinical data and…
Novo Nordisk Shares Face Mounting Headwinds
Novo Nordisk cuts 2026 sales outlook, faces FDA warnings and analyst downgrades as GLP-1 competition and pricing pressures…
Novo Nordisk Faces Mounting Competition in Key Diabetes Drug Market
Aspen Pharmacare targets 2026 generic Ozempic launch in Canada after semaglutide patent expiry, pressuring Novo Nordisk amid a…
Novo Nordisk Faces Mounting Challenges on Pricing and Pipeline
Novo Nordisk slashes US prices for Ozempic, Wegovy, and Rybelsus to $675/month in 2027. Its new obesity drug,…
Novo Nordisk Faces Mounting Pressure as Generic Rival Emerges
The Danish pharmaceutical giant’s commanding position in the weight-loss drug market is under significant threat. Novo Nordisk, already…
Logistics giant DSV adds PV array to warehouse roof
Approximately 78,000 solar panels have been installed by project developer SolarFuture on the roof of logistics company DSV…